Moderna, Inc.
Moderna is a biotechnology company that develops RNA-based medicines, primarily messenger-RNA (mRNA) vaccines. mRNA vaccines deliver genetic instructions that tell the body's own cells to make a protein and trigger an immune response; Moderna's COVID-19 vaccine used this approach. Unusually for a BDC borrower, Moderna is a publicly traded S&P 500 company (Nasdaq: MRNA).
Company profile compiled from public sources (company filings, rating-agency reports, and press releases) — distinct from the SEC Schedule-of-Investments pricing data below.
Lenders
Moderna, Inc. is held by 2 BDC lenders in our parsed SEC filings: AGTC, ARCC.
Cross-lender loan pricing
Each row is one debt tranche at the BDC’s most recent filing that holds this borrower, widest spread first. Mark is the position’s fair value as a percent of par (100 = par). Spread is shown in basis points over the benchmark in the Rate column, normalized from each filing’s as-reported units — rows quoting different benchmarks are still not directly comparable. Compare like-for-like: a second-lien tranche, a different vintage, or an older filing should price wider even when the credit view is identical — check the Type and Filing columns before reading a gap as disagreement. Source: SEC EDGAR (public).
| BDC | Type | Rate | Cash spread (bps) | Mark (% of par) | Fair Value | Maturity | Filing |
|---|---|---|---|---|---|---|---|
| AGTC | 1L Sr Secured | SOFR | 550 | 98.5 | $84M | 2030-11 | 2026-08-07 |
| ARCC | 1L Sr Secured | SOFR | 550 | 98.5 | $110M | 2030-11 | 2026-07-29 |
Marks reflect each BDC’s own fair-value estimates as reported to the SEC, not traded prices. Private-credit loans are predominantly Level 3 under ASC 820 — valued from unobservable inputs and determined in good faith by each BDC’s board, so figures are estimates as of the filing date and are not directly comparable across managers. Informational only; not investment advice or a valuation.
Ownership & deal activity
Headlines mentioning Moderna, Inc.
Public headlines that name Moderna, Inc., matched by company name and shown most-recent first. A mention is not an endorsement, a rating, or investment advice — verify anything material against the original source. Source: Google News.
- Why Is Moderna (MRNA) Stock Rocketing Higher Today
- Moderna, Inc. (MRNA) Stock Price, News, Quote & History
- FDA approves Moderna's mRNA seasonal flu vaccine
- Sanofi sues Pfizer, Moderna over COVID shot technology
- Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties
- Moderna Inc Stock (MRNA) Moved Down by 8.01% on Jul 10: Facts Behind the Movement
- Moderna, Inc. Stock 12‑Month Price Target Raised to $47.45, Implies 21% Downside
- Gov't Says It Should Face Vax IP Claims, Not Moderna
Reading this table
When two business development companies lend to the same borrower, comparing how each marks the loan is a starting question, not a verdict. In plain English: a wider spread (e.g. S+575 vs S+525) or a lower mark (e.g. 96 vs 100 cents on the dollar) can mean that lender is pricing in more risk — but marks can also differ for reasons other than a credit view: a different tranche (second lien should price wider than first lien on the same company), a different vintage or entry point, an older filing date, or each manager’s own fair-value methodology. Compare like-for-like — check the Type and Filing columns before reading a gap as disagreement. Each row is one debt position at one BDC’s most recent filing. Source: SEC EDGAR Schedule of Investments (public).
Want to read these numbers like an analyst? Free Oxford Ledge lessons: reading a BDC’s Schedule of Investments, key credit metrics, and the Five Cs of credit analysis.